3.9 Article

Estimating the Cost of 3 Risk Prediction Strategies for Potential Use in the United Kingdom National Breast Screening Program

Journal

MDM POLICY & PRACTICE
Volume 8, Issue 1, Pages -

Publisher

SAGE PUBLICATIONS INC
DOI: 10.1177/23814683231171363

Keywords

micro-costing; breast cancer screening; risk prediction; risk-based cancer screening

Ask authors/readers for more resources

This study identified and quantified the resource use and associated costs of introducing a breast cancer risk-stratification approach into the English national breast screening program. Findings showed that using questionnaires and automated breast density measurement for risk prediction had low costs, but adding SNP testing significantly increased the costs.
BackgroundEconomic evaluations have suggested that risk-stratified breast cancer screening may be cost-effective but have used assumptions to estimate the cost of risk prediction. The aim of this study was to identify and quantify the resource use and associated costs required to introduce a breast cancer risk-stratification approach into the English national breast screening program. MethodsA micro-costing study, conducted alongside a cohort-based prospective trial (BC-PREDICT), identified the resource use and cost per individual (; pound 2021 price year) of providing a risk-stratification strategy at a woman's first mammography. Costs were calculated for 3 risk-stratification approaches: Tyrer-Cuzick survey, Tyrer-Cuzick with Volpara breast-density measurement, and Tyrer-Cuzick with Volpara breast-density measurement and testing for 142 single nucleotide polymorphisms (SNP). Costs were determined for the intervention as implemented in the trial and in the health service. ResultsThe cost of providing the risk-stratification strategy was calculated to be 16.45 pound for the Tyrer-Cuzick survey approach, 21.82 pound for the Tyrer-Cuzick with Volpara breast-density measurement, and 102.22 pound for the Tyrer-Cuzick with Volpara breast-density measurement and SNP testing. LimitationsThis study did not use formal expert elicitation methods to synthesize estimates. ConclusionThe costs of risk prediction using a survey and breast density measurement were low, but adding SNP testing substantially increases costs. Implementation issues present in the trial may also significantly increase the cost of risk prediction. ImplicationsThis is the first study to robustly estimate the cost of risk-stratification for breast cancer screening. The cost of risk prediction using questionnaires and automated breast density measurement was low, but full economic evaluations including accurate costs are required to provide evidence of the cost-effectiveness of risk-stratified breast cancer screening.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.9
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available